Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Winlevi is being considered for hair loss by someone who wants to avoid systemic hormonal changes. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.
The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
A user's nine-month journey of hair growth with treatments including finasteride, minoxidil, and nizoral; some participants thought the user had a hair transplant while others disagreed.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
The user experienced severe scalp itching after using RU58841 and ketoconazole shampoo, despite trying moisturizing treatments. They suspect the issue is related to the propylene glycol in the vehicle and are seeking alternatives.
LeBron James likely uses hair transplants and possibly hair fibers or sprays to maintain his hairline, but his crown remains problematic. Despite his wealth, he hasn't fully resolved his hair loss, leading to speculation about his treatments and choices.
The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
The user switched from finasteride to dutasteride and is using minoxidil and RU58841 for hair loss treatment. They are satisfied with the progress and considering a hair transplant, despite some initial shedding after the medication change.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.
The user has been treating hair loss for 7 months using a combination of pyrilutamide, a topical mix of finasteride and minoxidil, microneedling, a topical mix of GHK-Cu and minoxidil, ketoconazole shampoo, fish collagen peptides, zinc, and vitamin D3. Another user suggests that continuous small improvements could lead to significant hair regrowth over time.
The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.
The user is considering switching from finasteride and RU58841 to dutasteride due to ongoing hair loss concerns. They are unsure if the hair loss is due to shedding or worsening condition.
A 24-year-old male shared his 9-month hair loss treatment journey, initially using topical finasteride and minoxidil, and recently switching to oral dutasteride and minoxidil. He experienced manageable shedding, noticeable hair density improvement, and plans to consider a hair transplant after 12-18 months on the oral treatment.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.
Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.